Cite
HARVARD Citation
Nanda, R. et al. (n.d.). Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study. European journal of cancer. pp. S38-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Nanda, R. et al. (n.d.). Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study. European journal of cancer. pp. S38-. [Online].